Gå til hovedindhold

​​​​​​​​

AMAZE - Vægttabsprojekt

Parker Instituttet deltager i test af ny vægttabsmedicin i et projekt, der ledes af NOVO Nordisk A/S. Medicinen, amycretin, forventes at give et vægttab på omkring 20%. Betingelser for deltagelse kan ses her siden. Der er tale om et lodtrækningsstudie, hvor personer med kombination af overvægt og knæartrose tilbydes deltagelse. To af 3 deltagere får medicinen, mens 1 af 3 får placebo. Behandlingen gives over et år med en del besøg, hvor der også ydes diætvejledning. 

 


AMAZE 5 og 6: vigtigste in- og eksklusionskriterier

 

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  1. Age 18 years or above at the time of signing the informed consent.
  2. History of at least one self-reported unsuccessful dietary effort to lose body weight.
  3. Body mass index (BMI) ≥ 27.0 kg/m2 at screening.
  4. Participant must have a desire and be committed to lose at least 25% of their body weight.
  5. (KL) grades 2 to 3 (AMAZE 6 : 2-4).
  6. Pain in the target knee > 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days.

Exclusion criteria

General safety

7.      History of pancreatitisa.

8.      Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) at screening.

9.      History of type 1 or type 2 diabetes mellitusa.

10.  Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes mellitus or pre-diabetes within 90 days before screening.

11.  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), within 1 year before screening.

Weight-related

12.  A self-reported change in body weight > 5% within 90 days before screening

13.  medication prescribed for the indication of obesity within 90 days before screening.

Mental health related

14.  Any history of suicidal attempta.or Suicidal behaviour within 30 days before screeninga.

15.  Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within 30 days before screening.

16.  A Patient Health Questionnaire 9 (PHQ-9) score of ≥ 15 as assessed at screening.

Osteoarthritis-related

17.  injections into target knee within the last 90 days prior to screening.

18.  Any other joint disease in target knee including gout and pseudogout.

19.  Chronic widespread pain.

 


Hvis du er interesseret i at høre mere eller deltage, er du velkommen til at sende en e-mail til  line.rustad@regionh.dk sammen med dit telefonnummer. En projektmedarbejder vil derefter kontakte dig så hurtigt som muligt.​



Sidst opdateret:
Redaktør
Klik for at scrolle op eller ned p� siden G� til toppen af siden